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The effect of duplicate isolate removal strategies on
Staphylococcal aureus susceptibility to oxacillin was com-
pared by using antimicrobial test results for 14,595 isolates
from statewide surveillance in Hawaii in 2002. No removal
was compared to most resistant and most susceptible
methods at 365 days and to the National Committee for
Clinical Laboratory Standards (NCCLS) and Cerner algo-
rithms at 3-, 10-, 30-, 90-, and 365-day analysis periods.
Overall, no removal produced the lowest estimates of sus-
ceptibility. Estimates with either NCCLS or Cerner differed
by <2% when the analysis period was the same; with either
method, the difference observed between a 90- and a 365-
day period was <1%. The effect of duplicate isolate removal
was greater for inpatient than outpatient settings.
Considering the ease of implementation and comparability
of results, we recommend using the first isolate of a given
species per patient to calculate susceptibility frequencies
for S. aureus to oxacillin.
S
urveillance of antimicrobial susceptibility is critical for
developing strategies to control increasing antimicro-
bial resistance. Aggregation of institutional antibiograms is
commonly proposed as a useful means of monitoring
antimicrobial resistance trends in a population (1–3).
However, inconsistencies in the methods used to generate
antibiogram susceptibility reports, particularly with regard
to duplicate isolate removal, make comparing data from
different facilities problematic (2,4–6).
To address this situation, in 2002, the National
Committee for Clinical Laboratory Standards (NCCLS,
currently known as the Clinical and Laboratory Standards
Institute) recommended using antimicrobial test results
from the first species isolate per patient, per period of data
analysis, to calculate susceptibility frequencies (7). Other
approaches currently in use include not removing any iso-
lates, counting only the most susceptible or most resistant
isolate from a patient per surveillance period, and applying
the Cerner laboratory management system, a widely used
software program (4).
Studies comparing the potential effect of using different
methods for duplicate isolate removal are limited, i.e., most
existing analyses are based on data from a single facility or
compared only a few of the many different options for
duplicate isolate removal (4–6). We evaluated the effects of
13 distinct duplicate isolate removal strategies on
Staphylococcus aureus susceptibility to oxacillin by using
antimicrobial susceptibility test results from a statewide
antimicrobial resistance surveillance system in Hawaii.
Methods and Materials
Data Collection 
All available susceptibility data for S. aureus isolates
identified in Hawaii in 2002 were collected retrospective-
ly from the laboratory information systems of participating
facilities and transferred to the State of Hawaii
Antimicrobial Resistance Project (SHARP) database. The
SHARP system consists of laboratory data from 2 large
commercial clinical laboratories and most acute-care hos-
pitals. The 2 commercial laboratories serve most of
Hawaii’s population (N = 1,211,537) by providing suscep-
tibility testing services for >85% of all nonhospital outpa-
tient settings in Hawaii and performing susceptibility
testing for 18 of the 24 acute-care hospitals in the state
(8,9). The remaining 6 acute-care hospitals each maintain
their own laboratory to perform susceptibility testing for
their respective facility. Susceptibility results from 3 of
these hospitals were incorporated into the SHARP
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(88%) of Hawaii’s 24 acute-care hospitals. A review of
antibiograms produced by all laboratories in Hawaii in
2001 indicates that the data sources used in the current
analysis capture >90% of all S. aureus identified in our
state annually.
Laboratories participating in SHARP provide isolate-
level data, including the specimen collection date, source
(e.g., blood, urine, and cerebrospinal fluid), susceptibility
test methods (e.g., Kirby-Bauer), and susceptibility test
results. Limited demographic patient information is also
included in the record, e.g., date of birth and sex, but
detailed clinical histories and patient names are not avail-
able. The susceptibility testing method used by all labora-
tories during the study period was the Vitek automatic
system, supported by the Kirby-Bauer disk diffusion
method (10). NCCLS criteria were used to interpret
inhibitory zone diameters and MIC. Determination of
methicillin susceptibility is based on oxacillin susceptibil-
ity testing. The breakpoint for oxacillin resistance was
MIC >4 µg/mL or a zone diameter <10 mm. The break-
point for intermediate isolates was MIC 2–4 µg/mL or
zone diameter 11–12 mm. The breakpoint for susceptible
isolates was MIC <2 µg/mL or zone diameter >13mm.
For this analysis, S. aureus isolates from inpatients in
intensive care units (ICUs), other inpatient settings (non-
ICU), and outpatient settings (e.g., physician offices, com-
munity health centers, hospital outpatients, and emergency
departments) were included. Isolates from patients in long-
term care homes and prisons were excluded.
Detection of Duplicate Isolates
Duplicate isolates were identified by using Microsoft
Access (Microsoft Corp., Redmond, WA, USA) to sort
susceptibility data based on the patient’s unique medical
record number (MRN), if available, or an assigned patient
identifier (APID). When an MRN was not available, the
APID was created from the patient’s date of birth, sex,
reporting laboratory, and identity of the hospital facility or
private physician who ordered the culture. The ability of
the APID to uniquely identify patients was assessed by
generating an APID for the subset of patients who also had
MRNs. The corresponding APID was found to be unique
for 99% of the records with a unique MRN and assessed to
be an acceptable surrogate. The potential effect of using
the APID in lieu of the MRN was assessed in a subanaly-
sis that compared the results for records containing an
MRN to those from records identified with the APID.
Methods for Duplicate Isolate Removal
Antimicrobial susceptibility frequencies were calculat-
ed by using each of the 5 duplicate isolate removal
methods described. For the “no removal” method,
susceptibility results for all S. aureus isolates in the 2002
database were included in the estimation of the proportion
of isolates. For the “most resistant” method, during a 365-
day period, irrespective of the number of positive cul-
tures, each patient was counted only once. For any given
patient, if a resistant isolate was identified, the first resist-
ant isolate identified was included in the analysis, and all
other results, susceptible or resistant, were censored. If no
resistant isolates were identified for a patient during the
period, the first sensitive isolate was included in the
analysis. For the “most susceptible” method, during a
365-day period, irrespective of the number of positive cul-
tures, each patient was counted only once. For any given
patient, if a susceptible isolate was identified, the first sus-
ceptible isolate identified was included in the analysis,
and all other results, susceptible or resistant, were exclud-
ed. If no susceptible isolates were identified for a patient
during the period, the first resistant isolate was included in
the analysis. For the NCCLS method, the susceptibility
results for the first S. aureus isolate per patient per analy-
sis period, irrespective of body site, antimicrobial suscep-
tibility profile, or other phenotypic characteristics (e.g.,
biotype), were included in the analysis (7). We applied
NCCLS criteria for 5 different surveillance periods: 3, 10,
30, 90, and 365 days. Finally, for the Cerner method, a
duplicate isolate was defined as from the same patient,
same species, and same NCCLS susceptibility category to
an individual antimicrobial agent as an immediately pre-
vious isolate (4). For this study, the Cerner method was
modified to include surveillance periods commonly used
with other duplicate isolate removal methods: 3, 10, 30,
90, and 365 days. Therefore, in our setting, duplicate S.
aureus isolates were defined by the modified Cerner
methods as the same patient and same susceptibility to
oxacillin as the immediately previous isolate found during
the same analysis period. Any isolate obtained from a
given patient during the period of analysis that showed a
change in susceptibility from that of the previous isolate
was included in calculations of susceptibility.
For each method, the percentage of susceptible isolates
was calculated by dividing the number of susceptible iso-
lates by the number of total isolates eligible for the inclu-
sion method in each particular analysis. Tables 1 and 2
show how the various strategies are applied to hypotheti-
cal patient isolates and illustrate how the susceptibility
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percent confidence intervals (CIs) for proportions of sus-
ceptibility were calculated by using the binomial method.
When susceptibility proportions for specific clinical set-
tings (or institutions) were calculated, only isolates
obtained in that particular setting (or institution) were eli-
gible for analysis.
Results
Susceptibility testing results were identified for 14,595
S. aureus clinical isolates obtained from 10,892 patients. A
total of 3,725 isolates were from 2,749 patients with an
associated MRN; 10,870 were from 8,143 patients identi-
fied with an APID. For all patients, the isolate-to-patient
ratio was 1.3.
Figure 1 depicts the effect of duplicate isolate removal
on  S. aureus susceptibility to oxacillin for all isolates.
NCCLS and Cerner methods produced similar estimates of
susceptibility for any given analysis period, i.e., the differ-
ence between the 2 methods was insignificant.
Furthermore, the difference in susceptibility percentage
between a 90-day and 365-day period was <1% by either
NCCLS or Cerner criteria, which was insignificant. With
both Cerner and NCCLS methods, the general trend for
estimates of susceptibility increased as the period of analy-
sis lengthened.
No removal resulted in the lowest susceptibility esti-
mate (67%) observed, even lower than that for most resist-
ant (Figure 1). Overall, an inverse relationship was
observed between number of isolates included in the
analysis and proportion of susceptible isolates (Figure 1).
For both Cerner and NCCLS methods, point estimates of
susceptibility rose slightly as the period of analysis
increased and the number of isolates included in the sus-
ceptibility calculations decreased.
The patterns observed for all isolates combined
remained unchanged when stratified by different clinical
settings, i.e., ICU, non-ICU, and outpatient (Table 3).
Within a given clinical setting, the difference in suscepti-
bility frequencies with the 90- and 365-day intervals by
either Cerner or NCCLS was <1%.
Differences in the magnitude of the effect of duplicate
isolate removal were observed across different clinical set-
tings (Table 3). For example, the effect of removal in the
non-ICU and ICU environments was an increase of 8%
and 6%, respectively, in the susceptible proportion when
comparing 365-day NCCLS results to no removal; this
comparison resulted in an increase of 2% in the outpatient
setting.
In a subanalysis restricted to the 2,749 patients (3,725
isolates) with an associated MRN, results were highly
analogous to those observed for the larger cohort as a
whole. Specifically, for each clinical setting, the difference
in the susceptibility estimate between NCCLS and Cerner
methods was insignificant for any given period of analysis,
and the difference in susceptibility percentage between a
90- and 365-day time period was <1% with either NCCLS
or Cerner. In addition, the outpatient setting continued to
show the least effect of duplicate isolate removal when
compared to inpatient settings.
Finally, we examined the effect of each deduplication
strategy for inpatients (ICU and non-ICU) at major hospi-
tals. Although the hospitals were of different sizes, and
their respective rates of MRSA differed by what was seen
with no removal, the effects of deduplication observed for
each hospital individually were similar to those observed
for the population-based surveillance dataset as a whole.
Figure 2 illustrates the results of isolate deduplication from
2 of the hospitals with the largest number of S. aureus iso-
lates in 2002.
Discussion
To our knowledge, this report is the first to compare the
effect of different deduplication strategies on susceptibili-
ty patterns derived from a statewide, population-based
antimicrobial resistance surveillance system. The relative-
ly large sample of S. aureus isolates in this study was
obtained from multiple healthcare settings by a variety of
clinical laboratories. Because of the diversity of practice
patterns represented in the study, we believe our findings
are likely to be applicable to other facilities and agencies
conducting antimicrobial resistance surveillance for
MRSA.
The major findings from this analysis are the following:
1) NCCLS and modified Cerner methods yield similar
results for a given analysis period; 2) with both NCCLS
and modified Cerner, the number of total isolates included
and the percentage that are MRSA decrease slightly as the
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portion of MRSA produced for a 90- or 365-day analysis
period were statistically similar by either NCCLS or
Cerner; and 4) the effect of deduplication was greater for
inpatient settings compared to outpatient settings.
We also found that no removal produced the highest
estimates of MRSA resistance, even higher than most
resistant for the same analysis period. While this finding
may seem at first paradoxical, it demonstrates the influ-
ence that practice patterns may have on reported rates of
MRSA and why deduplication is critical. In our setting,
cultures of samples from patients with MRSA were
obtained more frequently than cultures from those with
methicillin-susceptible strains (MSSA) so that, on average,
individual patients with MRSA contributed more isolates,
which could be included in the estimation of MRSA rates.
This fact also explains why we observed, for both NCCLS
and Cerner, an inverse relationship between the length of
the analysis period and the rate of MRSA, i.e., the greater
number of isolates included with shorter periods of analy-
sis meant more MRSAisolates relative to MSSAstrains. If
reculturing patient samples is influenced by prior suscepti-
bility testing results, an institution’s MRSA percentages
might be determined by the practice patterns of physicians
working within the institution. Furthermore, trends in
antimicrobial resistance could be obscured if practice pat-
terns changed and reculturing samples from MSRA
patients became more or less common.
Duplicate isolate removal facilitates comparing data
among institutions and monitoring trends over time.
However, at present, no clear consensus has been reached
on the definition of duplicate isolates, and duplicate iso-
lates cannot be easily identified with certainty in clinical
practice (2,4–6). Our study found that NCCLS and modi-
fied Cerner methods yield similar results, and for either a
90-day or a 365-day analysis period, the produced esti-
mates fall between results produced by the most resistant
and most susceptible methods. Thus, NCCLS and Cerner
might both be considered reasonable approaches.
However, the NCCLS method has 1 major advantage:
NCCLS is the only method that does not require the infec-
tion control practitioner to simultaneously compare sus-
ceptibility results for multiple isolates obtained from a
given patient during the analysis period. With NCCLS, one
simply includes the susceptibility results for the first iso-
late obtained during the analysis period. This straightfor-
ward approach would minimize opportunity for error and
result in more consistent implementation of the deduplica-
tion process (5).
Regardless of which deduplication strategy is selected,
the question remains which analysis period to adopt
(5,6,11). A longer surveillance period increases the proba-
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Figure 1. Effect of duplicate isolate removal strategies on the num-
ber of Staphylococcus aureus isolates and percentage susceptible
to oxacillin for all patients in Hawaii, 2002. The 95% confidence
interval for the proportion is shown in brackets. NR, no removal;
MR, most resistant; MS, most susceptible; N, NCCLS algorithm;
C, Cerner algorithm; the number indicates the days in the analysis
period.bility that an isolate representing a truly new resistance
event (rather than a duplicate) will be removed (11,12).
The purpose of antimicrobial resistance surveillance is to
assess temporal trends, evaluate intervention efforts, and
ultimately improve clinical outcomes on a population-
based level. While the treating clinician will need to con-
sider the susceptibility results for each isolate obtained
from the patient, and perhaps promptly change therapy in
response to new developments (13,14), population-based
recommendations for antimicrobial treatment are not like-
ly to be altered on the basis of 3, 10, or even 30 days of sur-
veillance data. Therefore, adopting either a 90- or 365-day
analysis period for MRSAsurveillance appears reasonable.
At the statewide level in Hawaii, the results seen with the
90- and 365-day NCCLS methods were nearly identical, so
either option would be appropriate.
Antibiograms should be individualized for specific
clinical areas within an institution (e.g., ICUs) (15,16). In
Hawaii, we observed differences in both MRSA rates as
well as the magnitude of the effect of deduplication among
the ICU, non-ICU, and outpatient settings; outpatient set-
tings had the least effect. The greater effect of deduplica-
tion among inpatients may result from both the higher rate
of MRSA among hospitalized patients and a greater likeli-
hood of inpatients, especially those with MRSA, to have
samples recultured compared to outpatients.
A major limitation of this analysis is that, because of
medical confidentiality issues, we did not have patients’
names. Since unique identities were determined by using
an MRN generated by the treating facility or medical plan,
a patient whose sample was cultured in >1 clinical facility
during the analysis period might be miscounted as 2
persons. Arelated concern is that some laboratories did not
provide the patient’s MRN; for these patients, we had to
use other information to generate an APID. While the
APID process was not perfect and a small proportion of
persons may have been misclassified as nonunique, a sub-
analysis that used only records with MRNs produced the
same pattern of results as the analysis that used the larger
dataset that incorporated the APID. This finding suggests
that any misclassifications that resulted from using the
APID did not substantially alter the relative effect of the
different deduplication strategies we studied.
A second limitation is that we only assessed oxacillin
resistance among S. aureus, so that conclusions regarding
the effect of deduplication on other microorganisms must
be made with caution. In addition, our analysis was not
stratified by specific anatomic culture site (e.g., blood vs.
skin); therefore, the effect of various deduplication strate-
gies on isolates from specific culture sites could not be
addressed.
A third limitation is that we did not include deduplica-
tion methods that take into account patterns of phenotypic
resistance to multiple antimicrobial agents simultaneously
(i.e., antibiotypes), as is practiced in some European coun-
tries (12). Tracking resistance by antibiotypes may show
the actual number of infectious events or the selection of
resistance occurring within the surveillance period. While
these tasks are important for surveillance in some settings,
the main purpose of our study was to evaluate a variety of
uncomplicated strategies for generating communitywide
susceptibility reports to specifically monitor MRSA trends
and guide selection of empiric therapy. Nevertheless, fur-
ther work is needed to examine the role of antibiotype sur-
veillance in population-based antimicrobial surveillance
systems.
We conclude that the NCCLS recommendation of
including the first isolate of a given species per patient per
analysis period, irrespective of body site, antimicrobial
susceptibility profile, or other phenotypic characteristics,
yielded results similar to other duplicate isolate removal
methods and is straightforward in its implementation.
Application of the techniques we examined had the same
effect regardless of the institution. To aid our understand-
ing of MRSA in both infection control practice and public
health, we urge the widespread adoption of an industry
standard. We suggest that adopting the 90- or 365-day
NCCLS method would be appropriate, taking into account
the goals of surveillance and the resources required.
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